{
    "clinical_study": {
        "@rank": "80631", 
        "arm_group": {
            "arm_group_label": "Gefitinib 250mg/d", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression, perform scheduled visits in investigational sites at interview day and complete related examinations during follow-up period."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the disease control rate (DCR) of gefitinib as\n      third-line retreatment in stage IIIB/IV NSCLC with EGFR 19del/L858R positive mutation\n      patients who had benefited from first-line gefitinib treatment with EGFR 19del/L858R\n      positive mutation and tumor progression after the second-line chemotherapy"
        }, 
        "brief_title": "Third-line Treatment of Gefitinib in NSCLC Patients", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Primary Study Objective: To evaluate the disease control rate (DCR) of gefitinib as\n           third-line retreatment in stage IIIB/IV NSCLC with EGFR 19del/L858R positive mutation\n           patients who had benefited from first-line gefitinib treatment with EGFR 19del/L858R\n           positive mutation and tumor progression after the second-line chemotherapy\n\n        -  Secondary Study Objectives: To evaluate objective response rate (ORR), progressive-free\n           survival (PFS), overall survival(OS) and quality of life (QoL) of gefitinib as\n           third-line retreatment in NSCLC patients To evaluate the safety of gefitinib as\n           third-line treatment in NSCLC patients\n\n        -  Exploratory analyses: To dynamically monitor EGFR mutation status and explore the\n           relationship with clinical outcome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The subject or legal guardian could understand and sign informed consent form.\n\n          2. Male or female aged 18 years or older;\n\n          3. Subjects were diagnosed with stage IIIB or IV NSCLC before starting the first dose of\n             gefitinib third-line treatment;\n\n          4. EGFR exon 19 deletion or exon 21 L858R substitution mutation confirmed;\n\n          5. ECOG performance status 0-2;\n\n          6. Life expectancy of at least 12 weeks or longer;\n\n          7. Has at least one measureable lesion by RECIST 1.1;\n\n          8. NSCLC of enrolled subjects previously progressed after first-line gefitinib treatment\n             (PFS \u2265 6 months) and progressed again after second-line chemotherapy (not limited for\n             chemotherapy regimen, \u2265 4 cycles of chemotherapy). Investigator considers adopting\n             third-line gefitinib retreatment;\n\n          9. Criteria for laboratory examinations:\n\n               -  Total bilirubin (TB) \u2264 1.5 times upper limit of normal\n\n               -  Aspartate aminotransferase(AST), alanine aminotransferase (ALT) \u22642 times upper\n                  limit of normal; for subjects with hepatic metastasis, AST,ALT\u2264  5 times upper\n                  limit of normal\n\n               -  Creatinine clearance\u226545ml/min\n\n        Exclusion Criteria:\n\n          1. Known severe hypersensitivity to gefitinib or any ingredients of the product;\n\n          2. Patients with prior exposure to agents directed at the EGFR axis except gefitinib\n             (e.g. erlotinib, cetuximab, trastuzumab) ;\n\n          3. Pre-existing interstitial lung disease or pulmonary fibrosis evidenced by CT scan at\n             baseline;\n\n          4. Neutrophil count <1.0\u00d7109/L or platelet count <50\u00d7109/L;\n\n          5. Severe infection, uncontrolled systemic disease (e.g cardiopulmonary insufficiency,\n             fatal arrhythmias, hepatitis, etc);\n\n          6. Pregnancy or breast-feeding;\n\n          7. Women of childbearing age refuse to take adequate contraception measures during\n             gefitinib treatment\n\n          8. Subjects with other malignant tumors combined;\n\n          9. Known or suspected brain metastases or spinal cord compression, unless treated with\n             surgery and/or radiation and stable without steroid treatment for at least 4 weeks\n             prior to the first dose of study medication;\n\n         10. Subjects are unable to take  medications orally or have digestive malabsorption;\n\n         11. Investigators consider subjects should not be involved in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933347", 
            "org_study_id": "CTONG1304"
        }, 
        "intervention": {
            "arm_group_label": "Gefitinib 250mg/d", 
            "description": "Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.", 
            "intervention_name": "Gefitinib", 
            "intervention_type": "Drug", 
            "other_name": "Iressa"
        }, 
        "intervention_browse": {
            "mesh_term": "Gefitinib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "contact": {
                "email": "yong_song6310@yahoo.com", 
                "last_name": "Yong Song, Ph.D", 
                "phone": "+86 13851761392"
            }, 
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210002"
                }, 
                "name": "Nanjing General Hospital of Nanjing Military Command"
            }, 
            "investigator": {
                "last_name": "Yong Song, Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Third-line Treatment of Gefitinib in NSCLC Patients Who Had Received First-line Gefitinib With EGFR 19del/L858R Mutation and Tumor Progression After the Second-line Chemotherapy: a Single-arm, Prospective and Multi-center Study", 
        "overall_official": {
            "affiliation": "Nanjing PLA General Hospital", 
            "last_name": "Yong Song, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease Control Rate (DCR)", 
            "safety_issue": "No", 
            "time_frame": "week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933347"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "objective response rate (ORR), progressive-free survival (PFS), overall survival(OS)", 
            "safety_issue": "No", 
            "time_frame": "until the death of last subject or 2 years after enrollment"
        }, 
        "source": "Guangdong Association of Clinical Trials", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangdong Association of Clinical Trials", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}